BeOne Medicines Officially Launches Following Redomiciliation to Switzerland, Ushering in a New Era of Global Oncology Leadership
BeOne Medicines Ltd. formerly known as BeiGene, Ltd., has officially entered a transformative new chapter in its corporate journey with the announcement of its new name and formal redomiciliation to Switzerland. This milestone marks more than a legal or geographic change—it represents the company’s renewed global vision and enduring commitment to advancing the field of oncology on a worldwide scale.
Announced today, the rebranding to BeOne and the establishment of its legal headquarters in Switzerland are now fully in effect, signaling the completion of a carefully orchestrated transition that began with shareholder approval on April 28. The move underscores the company’s broader strategy to enhance its operational base within a premier biopharmaceutical hub, thereby strengthening its ability to deliver cutting-edge cancer therapies to patients around the globe.
A Unified Mission Under a New Name
In a statement accompanying the announcement, John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, highlighted the deeper meaning behind the name change and redomiciliation. “BeOne represents more than a name change—it’s not only a reflection of who we are today as a leading global oncology company, but also our ambition to redefine what’s possible in oncology as we unite patients, families, scientists, physicians, governments, and other oncology public health stakeholders around the world in our shared mission against cancer,” Oyler said.
He went on to emphasize that while tremendous progress has been made, particularly with the rapid expansion of BRUKINSA® and TEVIMBRA™, BeOne’s mission is far from complete. “After 15 years of relentless innovation and strategic investment to boost our internal global capabilities, we are just getting started,” Oyler added.
This milestone reflects a broader cultural and strategic evolution for the company. While its foundational mission to improve outcomes for cancer patients remains unchanged, the new identity under BeOne encapsulates a more unified, purpose-driven approach—one that bridges scientific innovation, global collaboration, and equitable patient access.
Strategic Redomiciliation to Switzerland
The redomiciliation from the Cayman Islands to Switzerland was strategically chosen to align with BeOne’s long-term growth trajectory. Switzerland is widely regarded as one of the world’s foremost life sciences and biopharmaceutical hubs, home to leading scientific institutions, a highly skilled workforce, and a robust regulatory framework. These attributes make it an ideal location for BeOne to scale its operations, deepen its R&D footprint, and expand its influence within the global oncology ecosystem.
Switzerland’s central location within Europe also provides logistical and operational advantages, including proximity to key markets, improved access to international talent, and alignment with European regulatory bodies. The decision to redomicile is thus both a symbolic and practical step that supports BeOne’s ongoing global expansion.
While the full transition to the BeOne name and brand identity will occur in phases across the company’s operations on six continents, the corporate and legal foundations are already in place. This phased rollout ensures continuity of operations while allowing internal teams and external stakeholders to seamlessly adapt to the new brand.
Building a Global Oncology Powerhouse
BeOne’s ascent to a leadership position in oncology has been built on a foundation of bold scientific vision, deliberate investment, and operational agility. Through strategic development of internal R&D, clinical, and manufacturing capabilities, the company has created a vertically integrated infrastructure that supports its ambitious global pipeline.
At the heart of BeOne’s hematology portfolio is BRUKINSA® (zanubrutinib), a next-generation BTK inhibitor that has achieved best-in-class status in multiple treatment settings. BRUKINSA has earned the broadest label in its class and currently leads in new patient starts across all approved indications in the United States. It serves as the cornerstone of BeOne’s hematology strategy, complemented by sonrotoclax, a late-stage BCL2 inhibitor, and BGB-16673, a first-in-class BTK protein degrader developed using the company’s proprietary CDAC (covalent degrader antibody conjugate) platform.
In parallel, BeOne has made major strides in solid tumor oncology, with ongoing efforts to build strong franchises in breast, lung, and gastrointestinal cancers. The company is advancing novel therapies across several cutting-edge modalities, including multi-specific antibodies, antibody-drug conjugates (ADCs), and targeted protein degraders. This diverse toolkit gives BeOne a unique ability to tackle complex tumor biology and deliver differentiated therapeutic options.
Unmatched R&D Productivity and Global Trial Reach
One of the most striking indicators of BeOne’s innovation engine is the sheer pace at which it advances new candidates into clinical development. In 2024 alone, BeOne’s research team introduced 13 new molecular entities into the clinic—a feat that exceeds even the output of many large multinational pharmaceutical companies. This level of productivity is driven by a research organization composed of over 1,100 scientists, engineers, and investigators working collaboratively across global hubs.
The company’s “Fast to Proof-of-Concept” strategy exemplifies its nimble approach to early development. By quickly generating clinical data on investigational candidates, BeOne can make informed decisions on pipeline advancement while optimizing the allocation of R&D resources. Supporting this approach is a clinical development team of nearly 3,700 professionals who oversee trials in more than 45 countries. Collectively, they have enrolled over 25,000 patients in more than 170 clinical trials, accelerating access to novel therapies for patients worldwide.
This global trial infrastructure enables BeOne to conduct cost-effective, rapid, and diverse studies that enhance the generalizability of its findings and bolster regulatory submissions across geographies. It also serves as a platform for real-world evidence generation, health equity initiatives, and scientific collaborations with academic and government institutions.
A Robust and Scalable Manufacturing Network
Complementing its R&D and clinical capabilities, BeOne has made significant investments in advanced biomanufacturing. The company’s flagship manufacturing and clinical R&D facility, located at the Princeton West Innovation Campus in Hopewell, New Jersey, is a testament to this commitment. With an $800 million investment, this state-of-the-art site is equipped to support end-to-end drug development and scalable production for both clinical and commercial supply.
This facility enhances BeOne’s operational resilience, ensuring consistent quality control and reducing reliance on external supply chains. It also allows the company to respond flexibly to shifting demand and regulatory requirements in different markets. In addition to New Jersey, BeOne maintains a growing network of global manufacturing sites that support its expansion in the U.S., Europe, Asia-Pacific, and beyond.
A Unified Future in Oncology
As BeOne begins this new chapter under a unified global identity, its mission remains rooted in the same principles that have guided its journey thus far: scientific excellence, patient-centricity, and bold ambition. The company’s evolution—from a nascent biotech firm to a global oncology powerhouse—has been marked by relentless innovation, strategic foresight, and an unwavering dedication to improving the lives of people with cancer.
With a robust pipeline of over 50 investigational oncology assets, commercialized products gaining momentum in global markets, and a solid operational foundation in Switzerland, BeOne is well positioned to lead the next era of cancer treatment.
As Oyler aptly summarized, “We are just getting started.”
BeOne’s name, philosophy, and structure now align more closely than ever before—fitting for a company with its sights set firmly on transforming cancer care worldwide.
